CEO Chad Costley, MD, MBA, provided an update with Sophia Abene from ContagionLive on BlueWillow Biologics’ NanoVax® intranasal vaccine for H5N1, with Phase 1 trial data showing broad immune responses and no serious adverse events.
Rebuilding Trust in Intranasal Vaccines for Avian Flu and Other Respiratory Diseases
The NanoVax® Vaccine Platform: Pandemic Preparedness and the Role of Mucosal Immunity